153 related articles for article (PubMed ID: 21668318)
21. Intraoperative venous blood sampling to localize a small androgen-producing ovarian tumor.
Bohlmann MK; Rabe T; Sinn HP; Strowitzki T; Von Wolff M
Gynecol Endocrinol; 2005 Sep; 21(3):138-41. PubMed ID: 16335905
[TBL] [Abstract][Full Text] [Related]
22. [18F-FDG PET/CT in patients, treated for ovarian cancer, with elevated CA 125 levels but no evidence of recurrence on conventional imaging].
Bochev P; Bocheva Y; Klisarova A; Ivanov S; Dancheva J; Chaushev B
Akush Ginekol (Sofiia); 2012; 51(1):18-27. PubMed ID: 22639775
[No Abstract] [Full Text] [Related]
23. Leydig cell tumour and mature ovarian teratoma: rare androgen-secreting ovarian tumours in postmenopausal women.
Palha A; Cortez L; Tavares AP; Agapito A
BMJ Case Rep; 2016 Nov; 2016():. PubMed ID: 27803082
[TBL] [Abstract][Full Text] [Related]
24. Use of F 18-fluoro-D-glucose-positron emission tomography-computed tomography to localize a hilar cell tumor of the ovary.
McCarthy-Keith DM; Hill M; Norian JM; Millo C; McKeeby J; Armstrong AY
Fertil Steril; 2010 Jul; 94(2):753.e11-4. PubMed ID: 20362283
[TBL] [Abstract][Full Text] [Related]
25. Physiologic FDG uptake in the ovary together with an abdominal wall leiomyoma mimicking metastasizing ovarian cancer on PET/CT imaging.
Schwarz EI; Ramach C; Mende KA; Strobel K
Clin Nucl Med; 2009 Apr; 34(4):249-50. PubMed ID: 19300062
[TBL] [Abstract][Full Text] [Related]
26. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and localization of testosterone-producing ovarian tumors: imaging or biochemical evaluation.
Wang PH; Chao HT; Liu RS; Cho YH; Ng HT; Yuan CC
Gynecol Oncol; 2001 Dec; 83(3):596-8. PubMed ID: 11733978
[TBL] [Abstract][Full Text] [Related]
28. Postmenopausal androgen-secreting ovarian tumors: challenging differential diagnosis in two cases.
Arteaga E; Martinez A; Jaramilo J; Villaseca P; Cuello M; Valenzuela P; Gejman R; Blumel JE
Climacteric; 2019 Aug; 22(4):324-328. PubMed ID: 30623686
[TBL] [Abstract][Full Text] [Related]
29. Spectrum of fluorodeoxyglucose-positron emission tomography/computed tomography and magnetic resonance imaging findings of ovarian tumors.
Kitajima K; Ueno Y; Maeda T; Murakami K; Kaji Y; Kita M; Suzuki K; Sugimura K
Jpn J Radiol; 2011 Nov; 29(9):605-8. PubMed ID: 21956364
[TBL] [Abstract][Full Text] [Related]
30. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
31. Virilising ovarian tumour: a case associating a Sertoli-Leydig cell tumour and a Brenner tumour.
Persechini ML; Motton S; Leguevaque P; Donadille F; Escourrou G; Vierasu B; Hamdi S; Bennet A; Caron P
Gynecol Endocrinol; 2011 May; 27(5):345-50. PubMed ID: 20569103
[TBL] [Abstract][Full Text] [Related]
32. The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.
Sari O; Kaya B; Kara PO; Gedik GK; Celik C; Ozbek O; Serdengecti M
Rev Esp Med Nucl Imagen Mol; 2012; 31(1):3-8. PubMed ID: 21549452
[TBL] [Abstract][Full Text] [Related]
33. Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma.
Martínez-Román S; Ramirez PT; Oh J; Viciedo MG; MacApinlac HA
Gynecol Oncol; 2005 Mar; 96(3):888-91. PubMed ID: 15721446
[TBL] [Abstract][Full Text] [Related]
34. Calcified metastases from ovarian carcinoma highlighted by F-18 FDG PET/CT: report of two cases.
Hu SL; Zhou ZR; Zhang YJ
Abdom Imaging; 2012 Aug; 37(4):675-9. PubMed ID: 21898082
[TBL] [Abstract][Full Text] [Related]
35. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy.
De Iaco P; Musto A; Orazi L; Zamagni C; Rosati M; Allegri V; Cacciari N; Al-Nahhas A; Rubello D; Venturoli S; Fanti S
Eur J Radiol; 2011 Nov; 80(2):e98-103. PubMed ID: 20688446
[TBL] [Abstract][Full Text] [Related]
36. FDG PET/CT in serous psammocarcinoma of the ovary.
Dong A; Wang Y; Zuo C
Clin Nucl Med; 2014 May; 39(5):453-5. PubMed ID: 23510884
[TBL] [Abstract][Full Text] [Related]
37. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
38. 18F-FDG PET/CT and MR findings of ovarian carcinoid within a dermoid cyst.
Horikawa M; Shinmoto H; Soga S; Miyai K; Kaji T
Clin Nucl Med; 2014 Sep; 39(9):e392-4. PubMed ID: 24300346
[TBL] [Abstract][Full Text] [Related]
39. Ovarian Leydig cell tumor in a post-menopausal patient with severe hyperandrogenism.
Souto SB; Baptista PV; Braga DC; Carvalho D
Arq Bras Endocrinol Metabol; 2014 Feb; 58(1):68-75. PubMed ID: 24728167
[TBL] [Abstract][Full Text] [Related]
40. Placental-site trophoblastic tumor and fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography.
Çerçi SS; Erdemoglu E; Bozkurt KK; Yalçn Y; Erdemoglu E
Hell J Nucl Med; 2015; 18(3):264-7. PubMed ID: 26574698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
